Aevitas Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Aevitas Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,850	Closed	-$219K	–	123
2021 Q4	$219K	Sell	1,850 -1,500	-45%	-$188K	0.13%	115
2021 Q3	$449K	Sell	3,350 -400	-11%	-$60.6K	0.29%	85
2021 Q2	$607K	Hold	3,750	–	–	0.39%	67
2021 Q1	$301K	Hold	3,750	–	–	0.21%	93
2020 Q4	$204K	Buy	+3,750	New	+$136K	0.15%	113
2019 Q2	–	Sell	-700	Closed	-$11K	–	253
2019 Q1	$11K	Hold	700	–	–	0.01%	296
2018 Q4	$10K	Hold	700	–	–	0.01%	300
2018 Q3	$20K	Hold	700	–	–	0.02%	288
2018 Q2	$19K	Hold	700	–	–	0.02%	281
2018 Q1	$15K	Hold	700	–	–	0.02%	287
2017 Q4	$13K	Buy	+700	New	+$16.2K	0.01%	298

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aevitas Wealth Management's NTLA Position: Q1 2022 in Review

Aevitas Wealth Management sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 1,850 shares — an estimated $219K sold.

Aevitas Wealth Management first reported a position in NTLA in Q4 2017 and held it in 11 quarters. The position peaked at $607K in Q2 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

Aevitas Wealth Management reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
Aevitas Wealth Management sold 1,850 Intellia Therapeutics shares in Q1 2022, an estimated $219K.
Aevitas Wealth Management first reported a position in Intellia Therapeutics in Q4 2017 and held it in 11 quarters.
Aevitas Wealth Management's Intellia Therapeutics position peaked at $607K in Q2 2021.
348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Aevitas Wealth Management's 13F filing for Q1 2022, filed 25 Apr 2022.